Revised SPC: olanzapine tablets

Publisher:
Glenmark Pharmaceuticals Europe Ltd
Publication date:
08 March 2017

Abstract

Restless legs syndrome has been added as an uncommon adverse effect of treatment. This update is following a PRAC recommendation in October 2016